Abstract
Erythropoietin (Epo) is a glycoprotein hormone that is the prime regulator of erythropoiesis. Recombinant Epo is a highly effective pharmaceutical used to correct anemias associated with renal insufficiency, cancer and other diseases. Efforts to increase its efficacy in vivo by manipulating the proteins structure have met with some success, and novel Epo-like agents are in development. Additionally, efforts to create Epo mimetic agents are underway, as is the design of agents to increase endogenous production. Because Epo has tissue protective actions outside of erythropoiesis, other designs have focused on producing erythropoietically inactive molecules that still retain extra-hematopoietic activity. The demonstration that Epo can trigger signaling in some cancer cells with, potentially, adverse effects on patient health has raised warning signs in the medical community and has gained the attention of regulatory authorities.
Keywords: Erythropoietin, erythropoietin receptor, glycosylation, pegylation, fusion proteins, mimetics, heteroreceptor, cancer
Current Pharmaceutical Design
Title: Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Volume: 14 Issue: 13
Author(s): N. Debeljak and A. J. Sytkowski
Affiliation:
Keywords: Erythropoietin, erythropoietin receptor, glycosylation, pegylation, fusion proteins, mimetics, heteroreceptor, cancer
Abstract: Erythropoietin (Epo) is a glycoprotein hormone that is the prime regulator of erythropoiesis. Recombinant Epo is a highly effective pharmaceutical used to correct anemias associated with renal insufficiency, cancer and other diseases. Efforts to increase its efficacy in vivo by manipulating the proteins structure have met with some success, and novel Epo-like agents are in development. Additionally, efforts to create Epo mimetic agents are underway, as is the design of agents to increase endogenous production. Because Epo has tissue protective actions outside of erythropoiesis, other designs have focused on producing erythropoietically inactive molecules that still retain extra-hematopoietic activity. The demonstration that Epo can trigger signaling in some cancer cells with, potentially, adverse effects on patient health has raised warning signs in the medical community and has gained the attention of regulatory authorities.
Export Options
About this article
Cite this article as:
Debeljak N. and Sytkowski J. A., Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives, Current Pharmaceutical Design 2008; 14 (13) . https://dx.doi.org/10.2174/138161208799316393
DOI https://dx.doi.org/10.2174/138161208799316393 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters Bortezomib as an Antitumor Agent
Current Pharmaceutical Biotechnology Radiotherapy for Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy Image Fusion Based on Estimation Theory: Applied to PET/CT for Radiotherapy
Recent Patents on Medical Imaging Understanding Unmet Needs in the Older Acute Myeloid Leukemia (AML) Patient
Current Cancer Therapy Reviews Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics NF-κB Signature on the Aging Wall
Current Drug Metabolism Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Expression and Function of PPARs in Cancer Stem Cells
Current Stem Cell Research & Therapy CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery Lymphatic Drainage in Patients with Primary Cutaneous Melanoma - the Role of Lymphoscintigraphy in Sentinel Lymph Node Biopsy
Current Medical Imaging Molecular Dynamics Simulations of Proteins and Peptides: From Folding to Drug Design
Current Protein & Peptide Science Tissue-Specific Methylation of Long Interspersed Nucleotide Element-1 of Homo Sapiens (L1Hs) During Human Embryogenesis and Roles in Neural Tube Defects
Current Molecular Medicine Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry HPV and Therapeutic Vaccines: Where are We in 2010?
Current Cancer Therapy Reviews Molecular Architecture of Tumor Suppressor p53
Current Topics in Medicinal Chemistry Cancer Chemoprevention Drug Targets
Current Drug Targets